CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection
M. S. Pampusch, H. M. Abdelaal, E. K. Cartwright, J. S. Molden, B. C. Davey, J. D. Sauve, A. K. Rendahl, E. G. Rakasz, E. Connick, E. A. Berger, P. J. Skinner
This study evaluates CAR/CXCR5-T cell therapy in SIV-infected rhesus macaques, showing reduced viral loads and safety, with potential for HIV remission.
bioRxiv · Jul 26, 2021Immunology